Sarah Mgonja
Family · Harlan, IANPI 1811340425
Payments from drug & device makers
Across 75 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$149
- Novartis$120
- AbbVie$99
- Amgen$93
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$79
- Lilly USA, LLC$67
- plus $612 from 20 others
What the payments were for
- Food & beverage$1,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $149 |
| Novartis | 7 | $120 |
| AbbVie | 5 | $99 |
| Amgen | 7 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $79 |
| Lilly USA, LLC | 4 | $67 |
| Pfizer | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| AstraZeneca(2 entities) | 3 | $57 |
| Boehringer Ingelheim | 3 | $48 |
| Mylan Specialty L.p. | 3 | $47 |
| Johnson & Johnson(2 entities) | 3 | $41 |
| Agile Therapeutics, Inc. | 2 | $38 |
| Eisai Inc. | 2 | $37 |
| Merck | 2 | $29 |
| GSK | 2 | $28 |
| Alkermes, Inc. | 1 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Biogen | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Vertex | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$1,219 in reported general payments places this provider in the 85th percentile of 1,268 family providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 12 | $10,524 |
| Cefdinir | 27 | $499 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $93 |
| Cephalexin | 16 | $60 |
| Amoxicillin | 12 | $37 |
| Prednisone | 16 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $67 | $10,52412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,268 family providers in Iowa.
Other family in Harlan
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.